Keros Therapeutics (NASDAQ:KROS) Hits New 1-Year Low – Here’s What Happened

Keros Therapeutics, Inc. (NASDAQ:KROS) shares hit a new 52-week low on Monday . The stock traded as low as $15.67 and last traded at $15.98, with a volume of 228784 shares traded. The stock had previously closed at $16.42.

Analyst Ratings Changes

Several equities analysts have recently issued reports on KROS shares. Truist Financial decreased their price objective on Keros Therapeutics from $100.00 to $43.00 and set a “buy” rating for the company in a report on Monday, December 23rd. Wedbush reissued an “outperform” rating and issued a $84.00 price target on shares of Keros Therapeutics in a report on Thursday, November 7th. Guggenheim cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Monday, December 16th. Scotiabank decreased their target price on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research note on Friday, December 13th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Four investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $75.00.

Keros Therapeutics Stock Performance

The stock has a market capitalization of $637.99 million, a PE ratio of -3.02 and a beta of 1.20. The stock’s 50 day moving average is $50.54 and its two-hundred day moving average is $50.50.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue was up 4750.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.33) earnings per share. Equities research analysts expect that Keros Therapeutics, Inc. will post -5.26 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

Large investors have recently bought and sold shares of the business. KBC Group NV grew its position in shares of Keros Therapeutics by 52.0% in the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after purchasing an additional 280 shares during the last quarter. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics in the 3rd quarter valued at approximately $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in Keros Therapeutics in the second quarter valued at approximately $128,000. Finally, LMR Partners LLP acquired a new stake in Keros Therapeutics during the third quarter worth $213,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.